[Effects of d-thyroxine sodium on patients with hypercholesterolemia].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
D,L-alpha-Methyl-thyroxin-ethylester hydrochloride (etiroxate hydrochloride, CG 635, Skleronorm) has been proved to be highly effective in lowering serum lipids in rats. Even daily oral doses of 3.3 mumol etiroxate hydrochloride/kg (2.8 mg/kg) decrease serum cholesterol significantly in hypercholesterolemic rats. From a dose of 10 mg/kg upwards etiroxate hydrochloride also significantly reduces serum triglycerides. Etiroxate hydrochloride has much less effect on oxygen consumption, heart rate and heart weight of rats than have L-thyroxin and D-thyroxin, and its antigoitrogenic effect is also much slighter. As calculated from the ratio between relative effect on basal metabolism and relative effect on serum cholesterol, the relative therapeutic index of the compound is 10--35 in comparison to a relative therapeutic index of 1 for L-thyroxin and D-thyroxin.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.